A New Era in
Neurological Treatment

Our Science

Overview

At Vico, we’re revolutionizing the treatment of complex neurological conditions through precise genetic intervention. 

VO659: Breaking New Ground in Neurological Treatment

Our lead candidate, VO659, represents a groundbreaking advancement in genetic medicine through its innovative  mechanism of action:

Science Overview Icon Blue Check

Targets the mutation that causes disease

Science Overview Icon Blue Check

Preferentially reduces toxic mutant protein while preserving wildtype protein

Science Overview Icon Blue Check

Potential to impact nine distinct neurodegenerative disorders

Science Overview Icon Blue Check

Demonstrates potential for reduced dosing frequency through ASO chemistry

Beyond Symptom Management

Our approach transcends traditional treatment methods by:

  • Targeting the genetic source of disease
  • Offering potential disease-modifying effects
  • Providing hope for multiple patient populations
  • Maintaining precision in protein targeting

This strategic intervention represents more than a treatment–it’s a fundamental shift in how we approach genetic neurological disorders.

Precision Genetic Intervention for Neurological Diseases

At Vico, we are rewriting the approach to complex neurological conditions by directly targeting their genetic foundations. 

Scroll to Top
Leadership
Leadership micah mackison

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.